<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Alexion Pharmaceuticals - Wikipedia</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"XpoJtQpAICsAALCOBn4AAAEV","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Alexion_Pharmaceuticals","wgTitle":"Alexion Pharmaceuticals","wgCurRevisionId":946921704,"wgRevisionId":946921704,"wgArticleId":31443674,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Alexion_Pharmaceuticals","wgRelevantArticleId":31443674,"wgIsProbablyEditable":!0,"wgRelevantPageIsProbablyEditable":!0,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgMediaViewerOnClick":!0,
"wgMediaViewerEnabledByDefault":!0,"wgPopupsReferencePreviews":!1,"wgPopupsConflictsWithNavPopupGadget":!1,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFMode":"stable","wgMFAmc":!1,"wgMFAmcOutreachActive":!1,"wgMFAmcOutreachUserEligible":!1,"wgMFLazyLoadImages":!0,"wgMFDisplayWikibaseDescriptions":{"search":!0,"nearby":!0,"watchlist":!0,"tagline":!1},"wgMFIsPageContentModelEditable":!0,"wgWMESchemaEditAttemptStepOversample":!1,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q204727","wgCentralAuthMobileDomain":!0,"wgEditSubmitButtonLabelPublish":!0,"wgMinervaPermissions":{"watch":!0,"talk":!1},"wgMinervaFeatures":{"beta":!1,"mobileOptionsLink":!0,"categories":!1,"pageIssues":!0,"talkAtTop":!1,"historyInPageActions":!1,"overflowSubmenu":!1,"tabsOnSpecials":!1,"personalMenu":!1,"mainMenuExpanded":!1,"simplifiedTalk":!0},
"wgMinervaDownloadNamespaces":[0]};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.minerva.base.styles":"ready","skins.minerva.content.styles":"ready","skins.minerva.content.styles.images":"ready","mediawiki.hlist":"ready","mediawiki.ui.icon":"ready","mediawiki.ui.button":"ready","skins.minerva.icons.wikimedia":"ready","skins.minerva.mainMenu.icons":"ready","skins.minerva.mainMenu.styles":"ready","mobile.init.styles":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["site","mediawiki.page.startup","skins.minerva.options","skins.minerva.scripts","ext.gadget.switcher","ext.centralauth.centralautologin","ext.popups","mobile.init","ext.relatedArticles.readMore.bootstrap","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","mw.externalguidance.init","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.cite.styles%7Cext.wikimediaBadges%7Cmediawiki.hlist%7Cmediawiki.ui.button%2Cicon%7Cmobile.init.styles%7Cskins.minerva.base.styles%7Cskins.minerva.content.styles%7Cskins.minerva.content.styles.images%7Cskins.minerva.icons.wikimedia%7Cskins.minerva.mainMenu.icons%2Cstyles&amp;only=styles&amp;skin=minerva"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=minerva&amp;target=mobile"></script>
<meta name="generator" content="MediaWiki 1.35.0-wmf.28"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta name="theme-color" content="#eaecf0"/>
<meta name="viewport" content="initial-scale=1.0, user-scalable=yes, minimum-scale=0.25, maximum-scale=5.0, width=device-width"/>
<link rel="manifest" href="/w/api.php?action=webapp-manifest"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Alexion_Pharmaceuticals rootpage-Alexion_Pharmaceuticals stable issues-group-B skin-minerva action-view">
<div id="mw-mf-viewport">
	<div id="mw-mf-page-center">
		<a class="mw-mf-page-center__mask" href="#"></a>
		<header class="header-container header-chrome">
			<form class="header" action="/w/index.php" method="get">
				<nav class="navigation-drawer toggle-list view-border-box">
					<input type="checkbox" id="main-menu-input" class="toggle-list__checkbox" role="button" aria-labelledby="mw-mf-main-menu-button">
					<label for="main-menu-input" id="mw-mf-main-menu-button"
						class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-menu-base20 mw-ui-icon-flush-left toggle-list__toggle"
						title="Open main menu" data-event-name="ui.mainmenu">Open main menu</label>
					<div id="mw-mf-page-left" class="menu toggle-list__list view-border-box">
	<ul id="p-navigation">
			<li class="">
			    <a href="/wiki/Main_Page" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-home" data-event-name="menu.home"><span>Home</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Special:Random#/random" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-die " data-event-name="menu.random"><span>Random</span></a>
			</li>
			<li class="jsonly">
			    <a href="/wiki/Special:Nearby" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-mapPin nearby" data-event-name="menu.nearby"><span>Nearby</span></a>
			</li>
	</ul>
	<ul id="p-personal">
			<li class="">
			    <a href="/w/index.php?title=Special:UserLogin&amp;returnto=Alexion+Pharmaceuticals" class="menu__item--login mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-logIn " data-event-name="menu.login"><span>Log in</span></a>
			</li>
	</ul>
	<ul id="pt-preferences">
			<li class="jsonly">
			    <a href="/w/index.php?title=Special:MobileOptions&amp;returnto=Alexion+Pharmaceuticals" class="menu__item--settings mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-settings " data-event-name="menu.settings"><span>Settings</span></a>
			</li>
	</ul>
	<ul class="hlist">
			<li class="">
			    <a href="/wiki/Wikipedia:About" class="" data-event-name=""><span>About Wikipedia</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Wikipedia:General_disclaimer" class="" data-event-name=""><span>Disclaimers</span></a>
			</li>
	</ul>
</div>

					<label class="main-menu-mask" for="main-menu-input"></label>
				</nav>
				<div class="branding-box">
					<a href="/wiki/Main_Page">
						<span><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></span>
						
					</a>
				</div>
				<div class="search-box">
					<input class="search mw-ui-background-icon-search skin-minerva-search-trigger" type="search" name="search" id="searchInput"
						autocomplete="off" placeholder="Search Wikipedia" aria-label="Search Wikipedia"
						value="">
				</div>
				<nav class="minerva-user-navigation" aria-label="User navigation">
					<div><button id="searchIcon" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-search-base20 skin-minerva-search-trigger" type="submit">Search</button></div>
					
				</nav>
			</form>
		</header>
		<main id="content" class="mw-body">
			<div class="banner-container">
			<div id="siteNotice"></div>
			</div>
			
			<div class="pre-content heading-holder">
				<div class="page-heading">
					<h1 id="section_0">Alexion Pharmaceuticals</h1>
					<div class="tagline"></div>
				</div>
				<nav class="page-actions-menu">
	<ul id="page-actions" class="page-actions-menu__list">
		<li id="language-selector" class="page-actions-menu__list-item">
				<a id="" href="/wiki/Special:MobileLanguages/Alexion_Pharmaceuticals" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-language-base20 mw-ui-icon-with-label-desktop language-selector"
					data-mw="interface"
					data-event-name="menu.languages" role="button" title="Language">Language</a>
		</li>
		<li id="page-actions-watch" class="page-actions-menu__list-item">
				<a id="ca-watch" href="/w/index.php?title=Special:UserLogin&amp;returnto=Alexion+Pharmaceuticals" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-star-base20 mw-ui-icon-with-label-desktop watch-this-article mw-watchlink menu__item--page-actions-watch"
					data-mw="interface"
					data-event-name="menu.watch" role="button" title="Watch">Watch</a>
		</li>
		<li id="page-actions-edit" class="page-actions-menu__list-item">
				<a id="ca-edit" href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=0" class="edit-page menu__item--page-actions-edit mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 mw-ui-icon-with-label-desktop"
					data-mw="interface"
					data-event-name="menu.edit" role="button" title="Edit the lead section of this page">Edit</a>
		</li>
	</ul>
</nav>
<!-- version 1.0.2 (change every time you update a partial) -->

				
				
				<div class="minerva__subtitle"></div>
			</div>
			
			<div id="bodyContent" class="content"><div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><div class="mw-parser-output"><section class="mf-section-0" id="mf-section-0">
<p><b>Alexion Pharmaceuticals Inc.</b> is an American pharmaceutical company best known for its development of <a href="/wiki/Eculizumab" title="Eculizumab">Soliris</a>, a drug used to treat the rare disorders <a href="/wiki/Atypical_hemolytic_uremic_syndrome" title="Atypical hemolytic uremic syndrome">atypical hemolytic uremic syndrome</a> (aHUS) and <a href="/wiki/Paroxysmal_nocturnal_hemoglobinuria" title="Paroxysmal nocturnal hemoglobinuria">paroxysmal nocturnal hemoglobinuria</a> (PNH).<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">[3]</a></sup><sup id="cite_ref-Forbes_4-0" class="reference"><a href="#cite_note-Forbes-4">[4]</a></sup> The company is also involved in immune system research related to autoimmune diseases.  It employs around 2,400 people worldwide.<sup id="cite_ref-Everything_5-0" class="reference"><a href="#cite_note-Everything-5">[5]</a></sup> In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, <a href="/wiki/Connecticut" title="Connecticut">Connecticut</a>, not far from the company's starting point in the same city.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup></p><table class="infobox vcard" style="width:22em"><caption class="fn org">Alexion Pharmaceuticals, Inc.</caption><tbody><tr><td colspan="2" class="logo" style="text-align:center"><a href="/wiki/File:Alexion_Pharmaceuticals_logo.svg" class="image"><img alt="Alexion Pharmaceuticals logo.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/9/9e/Alexion_Pharmaceuticals_logo.svg/220px-Alexion_Pharmaceuticals_logo.svg.png" decoding="async" width="220" height="33" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/9e/Alexion_Pharmaceuticals_logo.svg/330px-Alexion_Pharmaceuticals_logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/9e/Alexion_Pharmaceuticals_logo.svg/440px-Alexion_Pharmaceuticals_logo.svg.png 2x" data-file-width="490" data-file-height="73"></a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/List_of_legal_entity_types_by_country" title="List of legal entity types by country">Type</a></div></th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Public_company" title="Public company">Public</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Ticker_symbol" title="Ticker symbol">Traded as</a></th><td style="line-height: 1.35em;"><div class="plainlist"><ul><li><a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>: <a rel="nofollow" class="external text" href="https://www.nasdaq.com/symbol/alxn">ALXN</a></li><li><a href="/wiki/NASDAQ-100" title="NASDAQ-100">NASDAQ-100</a> component</li><li><a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500</a> component</li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/International_Securities_Identification_Number" title="International Securities Identification Number">ISIN</a></th><td style="line-height: 1.35em;"><span class="plainlinks nourlexpansion"><a class="external text" href="https://tools.wmflabs.org/isin/?language=en&amp;isin=US0153511094">US0153511094 </a><a href="https://www.wikidata.org/wiki/Q204727?uselang=en#P946" title="Edit this on Wikidata"><img alt="Edit this on Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" style="vertical-align: text-top" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20"></a></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Industry</th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Pharmaceutical_industry" title="Pharmaceutical industry">Pharmaceutical</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founded</th><td style="line-height: 1.35em;">1992</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founder</th><td class="agent" style="line-height: 1.35em;">Leonard Bell</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Headquarters</th><td class="adr" style="line-height: 1.35em;"><div style="display: inline;" class="locality"><a href="/wiki/Boston,_Massachusetts" class="mw-redirect" title="Boston, Massachusetts">Boston</a>, <a href="/wiki/Massachusetts" title="Massachusetts">Massachusetts</a>, U.S.</div></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Key people</div></th><td class="agent" style="line-height: 1.35em;">Leonard Bell <small>(<a href="/wiki/Chairman" class="mw-redirect" title="Chairman">Chairman</a>)</small><br><a href="/wiki/Ludwig_N._Hantson" title="Ludwig N. Hantson">Ludwig N. Hantson</a> <small>(<a href="/wiki/Chief_Executive_Officer" class="mw-redirect" title="Chief Executive Officer">CEO</a>)</small></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Products</th><td style="line-height: 1.35em;"><a href="/wiki/Eculizumab" title="Eculizumab">Soliris</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Revenue</th><td style="line-height: 1.35em;"><span class="nowrap"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> <a href="/wiki/United_States_dollar" title="United States dollar">US$</a>3,551.1 million <span style="font-size:85%;">(2017)</span></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Earnings_before_interest_and_taxes" title="Earnings before interest and taxes">Operating income</a></div></th><td style="line-height: 1.35em;"><span class="nowrap"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> US$627.4 million <span style="font-size:85%;">(2017)</span></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Net_income" title="Net income">Net income</a></div></th><td style="line-height: 1.35em;"><span class="nowrap"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> US$443.3 million <span style="font-size:85%;">(2017)</span></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Asset" title="Asset">Total assets</a></span></th><td style="line-height: 1.35em;"><span class="nowrap"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> US$13,583.3 million <span style="font-size:85%;">(2017)</span></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Equity_(finance)" title="Equity (finance)">Total equity</a></span></th><td style="line-height: 1.35em;"><span class="nowrap"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> US$8,893.1 million <span style="font-size:85%;">(2017)</span></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Number of employees</div></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> 2,525 (2017)</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Website</th><td style="line-height: 1.35em;"><span class="url"><a rel="nofollow" class="external text" href="http://www.alxn.com">www<wbr></wbr>.alxn<wbr></wbr>.com</a></span></td></tr><tr><td colspan="2" style="text-align:center;line-height: 1.35em;"><b>Footnotes / references</b><br><sup id="cite_ref-1" class="reference"><a href="#cite_note-1">[1]</a></sup><sup id="cite_ref-2" class="reference"><a href="#cite_note-2">[2]</a></sup></td></tr></tbody></table><p>In September 2017, Alexion announced it would be moving its headquarters to <a href="/wiki/Boston,_Massachusetts" class="mw-redirect" title="Boston, Massachusetts">Boston, Massachusetts</a>, in mid-2018.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">[7]</a></sup></p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none"><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul><li class="toclevel-1 tocsection-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a>
<ul><li class="toclevel-2 tocsection-2"><a href="#Acquisitions"><span class="tocnumber">1.1</span> <span class="toctext">Acquisitions</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Acquisition_history"><span class="tocnumber">1.2</span> <span class="toctext">Acquisition history</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-4"><a href="#Ownership"><span class="tocnumber">2</span> <span class="toctext">Ownership</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Products"><span class="tocnumber">3</span> <span class="toctext">Products</span></a>
<ul><li class="toclevel-2 tocsection-6"><a href="#Specialty_drugs"><span class="tocnumber">3.1</span> <span class="toctext">Specialty drugs</span></a>
<ul><li class="toclevel-3 tocsection-7"><a href="#Soliris"><span class="tocnumber">3.1.1</span> <span class="toctext">Soliris</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Strensiq"><span class="tocnumber">3.1.2</span> <span class="toctext">Strensiq</span></a></li>
<li class="toclevel-3 tocsection-9"><a href="#Kanuma"><span class="tocnumber">3.1.3</span> <span class="toctext">Kanuma</span></a></li>
</ul></li>
</ul></li>
<li class="toclevel-1 tocsection-10"><a href="#Financials"><span class="tocnumber">4</span> <span class="toctext">Financials</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-12"><a href="#External_links"><span class="tocnumber">6</span> <span class="toctext">External links</span></a></li>
</ul></div>

</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(1)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="History">History</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=1" title="Edit section: History" data-section="1" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-1 collapsible-block" id="mf-section-1">
<p>Alexion Pharmaceuticals was founded in 1992 at <a href="/wiki/Science_Park" class="mw-redirect" title="Science Park">Science Park</a> in <a href="/wiki/New_Haven,_Connecticut" title="New Haven, Connecticut">New Haven, Connecticut</a> by Steven Squinto and Leonard Bell.<sup id="cite_ref-medpage_8-0" class="reference"><a href="#cite_note-medpage-8">[8]</a></sup><sup id="cite_ref-:0_9-0" class="reference"><a href="#cite_note-:0-9">[9]</a></sup> Bell served as the company's CEO until 2015.<sup id="cite_ref-WSJ_10-0" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup> In 2000, Alexion moved its headquarters from New Haven to <a href="/wiki/Cheshire,_Connecticut" title="Cheshire, Connecticut">Cheshire, Connecticut</a>. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015.
</p><p>Since 2006, Alexion has been a supporter of healthcare research and quality studies at <a href="/wiki/Duke_University" title="Duke University">Duke University</a> for aspirin and <a href="/wiki/Clopidogrel" title="Clopidogrel">Clopidogrel</a> (trade name <b>Plavix</b>).<sup id="cite_ref-medpage_8-1" class="reference"><a href="#cite_note-medpage-8">[8]</a></sup></p><p>Alexion received U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (<a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">FDA</a>) approval for Soliris in 2007. It was initially approved to treat <a href="/wiki/Paroxysmal_nocturnal_hemoglobinuria" title="Paroxysmal nocturnal hemoglobinuria">paroxysmal nocturnal hemoglobinuria</a>, a rare blood disorder.<sup id="cite_ref-Everything_5-1" class="reference"><a href="#cite_note-Everything-5">[5]</a></sup>  In 2010, there was an outbreak of <a href="/wiki/Hemolytic-uremic_syndrome" class="mw-redirect" title="Hemolytic-uremic syndrome">hemolytic-uremic syndrome</a> caused by <a href="/wiki/Verotoxin-producing_Escherichia_coli" class="mw-redirect" title="Verotoxin-producing Escherichia coli">Enterohaemorrhagic Escherichia coli</a> (EHEC) in Germany.  Soliris was considered a treatment option because of its effectiveness in treating <a href="/wiki/Atypical_hemolytic_uremic_syndrome" title="Atypical hemolytic uremic syndrome">Atypical hemolytic uremic syndrome</a>, an illness similar to the one caused by the EHEC infection.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11">[11]</a></sup></p><p>In April 2011, Alexion was added to the <a href="/wiki/NASDAQ-100" title="NASDAQ-100">NASDAQ-100</a>, a group composed of the 100 largest non-financial stocks traded on the <a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>; with a market value of USD 8.5 billion it replaced <a href="/wiki/Genzyme" title="Genzyme">Genzyme Corporation</a>.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">[12]</a></sup></p><p>In April 2015, Bell was replaced as CEO by David Hallal.<sup id="cite_ref-WSJ_10-1" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup> In 2016, the company became a member of the <a href="/wiki/Pharmaceutical_Research_and_Manufacturers_of_America" title="Pharmaceutical Research and Manufacturers of America">Pharmaceutical Research and Manufacturers of America</a> (PhRMA).<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">[13]</a></sup></p><p>In December 2016, Alexion's board of directors announced new leadership. David Brennan, a current board member, became interim CEO. David Anderson, formerly the CFO of <a href="/wiki/Honeywell" title="Honeywell">Honeywell</a>, was appointed CFO, replacing Vikas Sinha.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">[14]</a></sup> In March 2017, Alexion named <a href="/wiki/Ludwig_N._Hantson" title="Ludwig N. Hantson">Ludwig N. Hantson</a> as its new CEO.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">[15]</a></sup></p><p>In September 2017, Alexion announced that it would be closing its Smithfield, RI manufacturing facility.
</p>
<h3 class="in-block"><span class="mw-headline" id="Acquisitions">Acquisitions</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=2" title="Edit section: Acquisitions" data-section="2" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>In 2000, Alexion purchased Proliferon Inc., a <a href="/wiki/San_Diego,_California" class="mw-redirect" title="San Diego, California">San Diego, California</a>-based development-stage biopharmaceutical firm, for US$41 million in Alexion stock. Alexion CEO, Leonard Bell, cited Proliferon's ability to produce an "unlimited amount of antibodies" as the reason for the acquisition.  At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">[16]</a></sup><sup id="cite_ref-17" class="reference"><a href="#cite_note-17">[17]</a></sup> The company has since been renamed Alexion Antibody Technologies Inc.
</p><p>In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder <a href="/wiki/Hypophosphatasia" title="Hypophosphatasia">hypophosphatasia</a>.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">[18]</a></sup></p><p>In May 2015, Alexion announced plans to purchase the Lexington firm <a href="/wiki/Synageva_BioPharma" class="mw-redirect" title="Synageva BioPharma">Synageva BioPharma</a>, a maker of rare disease treatments, in a $8.4 billion stock-and-cash deal.<sup id="cite_ref-bostonglobe_2015_19-0" class="reference"><a href="#cite_note-bostonglobe_2015-19">[19]</a></sup> The price represented more than a 135% premium over Synageva's market cap at the time.<sup id="cite_ref-WSJ_10-2" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup> It also represented a valuation of about ten times projected peak sales, double what is typical for the biotech industry.<sup id="cite_ref-NYT_20-0" class="reference"><a href="#cite_note-NYT-20">[20]</a></sup></p><p>In April 2018, Alexion announced the acquisition of <a href="/wiki/Wilson_Therapeutics" title="Wilson Therapeutics">Wilson Therapeutics</a> for $855 million.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup><sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup> In September the company announced it was to acquire <a href="/w/index.php?title=Syntimmune&amp;action=edit&amp;redlink=1" class="new" title="Syntimmune (page does not exist)">Syntimmune</a> for $1.2 billion - expanding its rare disease offering.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24">[24]</a></sup></p><p>In October 2019, the business announced it would acquire <a href="/w/index.php?title=Achillion_Pharmaceuticals&amp;action=edit&amp;redlink=1" class="new" title="Achillion Pharmaceuticals (page does not exist)">Achillion Pharmaceuticals</a> for $930 million, boosting its immune system disease pipeline.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">[25]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Acquisition_history">Acquisition history</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=3" title="Edit section: Acquisition history" data-section="3" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>The following is an illustration of the company's mergers, acquisitions, <a href="/wiki/Corporate_spin-off" title="Corporate spin-off">spin-offs</a> and historical predecessors:
</p>
<style data-mw-deduplicate="TemplateStyles:r935768785">.mw-parser-output table.clade{border-spacing:0;margin:0;font-size:100%;line-height:100%;border-collapse:separate;width:auto}.mw-parser-output table.clade table.clade{width:100%}.mw-parser-output table.clade td.clade-label{width:0.7em;padding:0 0.15em;vertical-align:bottom;text-align:center;border-left:1px solid;border-bottom:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-fixed-width{overflow:hidden;text-overflow:ellipsis}.mw-parser-output table.clade td.clade-fixed-width:hover{overflow:visible}.mw-parser-output table.clade td.clade-label.first{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-label.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-slabel{padding:0 0.15em;vertical-align:top;text-align:center;border-left:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-slabel:hover{overflow:visible}.mw-parser-output table.clade td.clade-slabel.last{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-slabel.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-bar{vertical-align:middle;text-align:left;padding:0 0.5em;position:relative}.mw-parser-output table.clade td.clade-bar.reverse{text-align:right;position:relative}.mw-parser-output table.clade td.clade-leaf{border:0;padding:0;text-align:left}.mw-parser-output table.clade td.clade-leafR{border:0;padding:0;text-align:right}.mw-parser-output table.clade td.clade-leaf.reverse{text-align:right}.mw-parser-output table.clade:hover span.linkA{background-color:yellow}.mw-parser-output table.clade:hover span.linkB{background-color:green}</style><table class="clade" style="font-size:90%;line-height:110%"><tbody><tr><td class="clade-label first" style="border-left:none;border-right:none;border-bottom:0px solid;"><b>Alexion Pharmaceuticals</b>
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Alexion Pharmaceuticals<br><small>(Founded 1992)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Proliferon Inc<br><small>(Acq 2000, restructured into Alexion Antibody Technologies Inc)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Enobia Pharma Corp<br><small>(Acq 2011)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/wiki/Synageva_BioPharma" class="mw-redirect" title="Synageva BioPharma">Synageva BioPharma</a><br><small>(Acq 2015)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/wiki/Wilson_Therapeutics" title="Wilson Therapeutics">Wilson Therapeutics</a><br><small>(Acq 2018)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/w/index.php?title=Syntimmune&amp;action=edit&amp;redlink=1" class="new" title="Syntimmune (page does not exist)">Syntimmune</a><br><small>(Acq 2018)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/w/index.php?title=Achillion_Pharmaceuticals&amp;action=edit&amp;redlink=1" class="new" title="Achillion Pharmaceuticals (page does not exist)">Achillion Pharmaceuticals</a><br><small>(Acq 2019)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last" style="border-right:none;border-left:none;"> 
</td></tr></tbody></table></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(2)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Ownership">Ownership</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=4" title="Edit section: Ownership" data-section="4" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-2 collapsible-block" id="mf-section-2">
<p>As of 2017 Alexion Pharmaceuticals shares are mainly held by institutional investors (<a href="/wiki/Fidelity_Investments" title="Fidelity Investments">Fidelity Investments</a>, <a href="/wiki/T._Rowe_Price" title="T. Rowe Price">T. Rowe Price</a>, <a href="/wiki/BlackRock" title="BlackRock">BlackRock</a> and others<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">[26]</a></sup>)
</p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(3)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Products">Products</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=5" title="Edit section: Products" data-section="5" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-3 collapsible-block" id="mf-section-3">
<h3 class="in-block"><span class="mw-headline" id="Specialty_drugs">Specialty drugs</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=6" title="Edit section: Specialty drugs" data-section="6" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Specialty_drugs" class="mw-redirect" title="Specialty drugs">Specialty drugs</a></div>
<p>Alexion has employed a strategy of developing drugs to combat rare diseases.  Since the targeted user base is small for such drugs, clinical drugs tend to be quicker<sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Vagueness" title="Wikipedia:Vagueness"><span title="This information is too vague. (June 2018)">vague</span></a></i>]</sup> and cheaper than those for mass market drugs.  Additionally, big pharmaceutical companies have tended to ignore these markets, creating a niche with minimal competition for Alexion.  Insurance companies have generally been willing to pay high prices for such drugs; since few of their customers need the drugs, a high price does not significantly impact the insurance companies' outlays.<sup id="cite_ref-NYT_20-1" class="reference"><a href="#cite_note-NYT-20">[20]</a></sup> "The success of specialty drugs for rare diseases comes at a time when the traditional drug business of selling medicines to the masses is in decline...Specialty drugs have gotten more expensive than anyone imagined."<sup id="cite_ref-Forbes_2010_27-0" class="reference"><a href="#cite_note-Forbes_2010-27">[27]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Soliris">Soliris</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=7" title="Edit section: Soliris" data-section="7" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Eculizumab" title="Eculizumab">Eculizumab</a></div>
<p>Alexion's first drug, Soliris, first launched in 2007,<sup id="cite_ref-:0_9-1" class="reference"><a href="#cite_note-:0-9">[9]</a></sup> used to treat the rare disorders <a href="/wiki/Atypical_hemolytic_uremic_syndrome" title="Atypical hemolytic uremic syndrome">atypical hemolytic uremic syndrome</a> (aHUS) and <a href="/wiki/Paroxysmal_nocturnal_hemoglobinuria" title="Paroxysmal nocturnal hemoglobinuria">Paroxysmal nocturnal hemoglobinuria</a> (PNH).<sup id="cite_ref-Forbes_4-1" class="reference"><a href="#cite_note-Forbes-4">[4]</a></sup>  It has been approved for use in Canada, the European Union, Japan, and the United States; however, availability in Canada is limited.  In Canada, access to the drug is mostly through private clinics; groups such as the Canadian Association of PNH Patients are lobbying to change that.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">[28]</a></sup>  The drug costs roughly $450,000 a year, and is considered the world's most expensive drug.<sup id="cite_ref-Everything_5-2" class="reference"><a href="#cite_note-Everything-5">[5]</a></sup><sup id="cite_ref-WSJ_10-3" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup> The price of the drug is so high that very few individuals can pay the price. As a result, Alexion hires public relations firms to help families institute campaigns to pressure their governments to pay for the drug. Alexion is putting pressure on to governments to receive their payments from the public purse. The prices charged have a very high margin above the cost price. In addition, much of the research for the development of Soliris originates from publicly funded universities. There is an ethical question as to the pricing of the drug and the ethics of the drug manufacturer. Alexion is well on the way to developing a second very high price and high margined drug.<sup id="cite_ref-CBC_2015_29-0" class="reference"><a href="#cite_note-CBC_2015-29">[29]</a></sup></p><p>In September 2011, the FDA officially approved the use of Soliris as a treatment for <a href="/wiki/Hemolytic-uremic_syndrome#Atypical_cases" class="mw-redirect" title="Hemolytic-uremic syndrome">atypical hemolytic-uremic syndrome</a> in both adults and children.  More than half of people with aHUS end up dying of it as a result of damage to vital organs/organ failure (usually involving the kidneys) caused by uncontrolled complement activation.  The FDA's decision to grant approval received a positive response from the medical community with the director of Pediatric Nephrology at Atlanta's Children's hospital calling it "the most important advance that has been made for patients and families with this disease".<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">[30]</a></sup></p><p>By 2010 Soliris was considered to be the most expensive drug in the world.<sup id="cite_ref-Forbes_2010_27-1" class="reference"><a href="#cite_note-Forbes_2010-27">[27]</a></sup> It costs £340,200 per year for treatment in the UK<sup id="cite_ref-irishtimes.com_31-0" class="reference"><a href="#cite_note-irishtimes.com-31">[31]</a></sup><sup id="cite_ref-nice.org.uk_32-0" class="reference"><a href="#cite_note-nice.org.uk-32">[32]</a></sup> and $500,000 a year in Canada.<sup id="cite_ref-irishtimes.com_31-1" class="reference"><a href="#cite_note-irishtimes.com-31">[31]</a></sup><sup id="cite_ref-nice.org.uk_32-1" class="reference"><a href="#cite_note-nice.org.uk-32">[32]</a></sup><sup id="cite_ref-Gallant_2014_33-0" class="reference"><a href="#cite_note-Gallant_2014-33">[33]</a></sup> and US$409,500 a year in the United States (2010).<sup id="cite_ref-Forbes_2010_27-2" class="reference"><a href="#cite_note-Forbes_2010-27">[27]</a></sup> In the case of the rarest diseases that afflict fewer than 10,000 people, biotech companies who own the only approved drugs to treat those diseases "can charge pretty much whatever they want." "Before testing Soliris for PNH, Alexion tested the drug for <a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">rheumatoid arthritis</a>, which afflicts 1 million Americans. The trials failed. But if it had worked for arthritis, Alexion would likely have had to charge a much lower price for this use, as it would have to compete against drugs that cost a mere $20,000." Alexion started selling Soliris in 2008 making $295 million in 2007 with its stock price rising to 130% in 2010.<sup id="cite_ref-Gallant_2014_33-1" class="reference"><a href="#cite_note-Gallant_2014-33">[33]</a></sup></p><p>In April and May 2013, a controversy arose in Belgium when the media revealed that the government had refused to pay for a seven-year-old boy's treatment because Soliris was too expensive.  The boy's medicine cost 9,000 euros every two weeks.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">[34]</a></sup>  On May 4, 2013, <i><a href="/wiki/De_Standaard" title="De Standaard">De Standaard</a></i> reported that a press relations (PR) agency working for Alexion had helped the boy's parents communicate their story to the press.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">[35]</a></sup> It was also reported that the parents had believed their benefactor was a Dutch organization for patients, and that the PR agency acted with permission from Alexion.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup><sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup>  Several politicians stated that the company was attempting to 'blackmail' the government, charges which Alexion denied.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">[38]</a></sup>  By May 7, 2013 an agreement had been reached to reimburse the medicine.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">[39]</a></sup><sup id="cite_ref-dm20150323_40-0" class="reference"><a href="#cite_note-dm20150323-40">[40]</a></sup></p><p>Pharma, the Belgian pharmaceutical industry's association, opened an internal investigation into the affair, for possible breach of the association's ethical standards by Alexion. However, on June 12, Alexion received a court <a href="/wiki/Gag_order" title="Gag order">gag order</a> against Pharma, preventing it from communicating its investigation. At the same time, Pharma opened a court case against Alexion Pharma Belgium. The gag order was revoked by the end of September 2013,<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">[41]</a></sup> but the case was still pending in March 2015.<sup id="cite_ref-dm20150323_40-1" class="reference"><a href="#cite_note-dm20150323-40">[40]</a></sup></p><p>In October 2017 the FDA approved the use of Soliris to treat adult patients with generalized <a href="/wiki/Myasthenia_gravis" title="Myasthenia gravis">myasthenia gravis</a> (gMG).<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup> In November 2017 the company received a patent for Soliris from the <a href="/wiki/Japan_Patent_Office" title="Japan Patent Office">Japanese Patent Office</a>.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43">[43]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Strensiq">Strensiq</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=8" title="Edit section: Strensiq" data-section="8" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In October 2015, Alexion's second drug, Strensiq (<a href="/wiki/Asfotase_alfa" title="Asfotase alfa">asfotase alfa</a>), was approved by the US FDA. It is used to treat <a href="/wiki/Hypophosphatasia" title="Hypophosphatasia">hypophosphatasia</a>, a rare metabolic disorder.
</p>
<h4 class="in-block"><span class="mw-headline" id="Kanuma">Kanuma</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=9" title="Edit section: Kanuma" data-section="9" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p><a href="/wiki/Kanuma_(drug)" class="mw-redirect" title="Kanuma (drug)">Kanuma</a>, which Alexion acquired in its acquisition of Synageva, was approved in 2015 to treat <a href="/wiki/Lysosomal_acid_lipase_deficiency" title="Lysosomal acid lipase deficiency">lysosomal acid lipase deficiency</a>, a fatal genetic disorder that cause fatty material to build up in blood vessel walls, the liver, and other tissues.<sup id="cite_ref-WSJ_10-4" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup>  Alexion estimates that the drug could eventually have annual sales of more than $1 billion.<sup id="cite_ref-AP_44-0" class="reference"><a href="#cite_note-AP-44">[44]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(4)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Financials">Financials</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=10" title="Edit section: Financials" data-section="10" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-4 collapsible-block" id="mf-section-4">
<p>In 2013, 36% Alexion's sales originated in the US, down from 37% the previous year; 33% came from Europe, down from 35%; Japan accounted for just over 10%.  Revenue was impacted by higher unit volumes for Soliris (up 40%), and a decreased average price  related to rebates in Europe.  Acquisition related costs fell significantly from $22 million to just $5 million.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup>   R&amp;D spending reached a record high of $317 million in 2013 up 83% from the previous year.<sup id="cite_ref-medpage_8-2" class="reference"><a href="#cite_note-medpage-8">[8]</a></sup></p><p>When Soliris was first approved, peak annual sales were estimated at $150 million.<sup id="cite_ref-NYT_20-2" class="reference"><a href="#cite_note-NYT-20">[20]</a></sup>  However, by September 2013 quarterly sales of Soliris topped $400 million.  Sales during the first quarter of 2015 were just over US$600 million, and are still on the rise.<sup id="cite_ref-WSJ_10-5" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup><sup id="cite_ref-NYT_20-3" class="reference"><a href="#cite_note-NYT-20">[20]</a></sup></p><p>Before the Synageva purchase announcement, Alexion was valued at $34 billion.<sup id="cite_ref-WSJ_10-6" class="reference"><a href="#cite_note-WSJ-10">[10]</a></sup>  The stock is up roughly 800% in the last five years and is currently trading at 46 times estimated earnings.  Due to the niche nature of its market and the high cost of Soliris, the company has enjoyed a high profit margin.<sup id="cite_ref-NYT_20-4" class="reference"><a href="#cite_note-NYT-20">[20]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(5)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="References">References</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=11" title="Edit section: References" data-section="11" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-5 collapsible-block" id="mf-section-5">
<div class="reflist" style="list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="references"><li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn10k12312017.htm">"Alexion Pharmaceuticals 2017 Annual Report Form (10-K)"</a>. <a href="/wiki/U.S._Securities_and_Exchange_Commission" title="U.S. Securities and Exchange Commission">U.S. Securities and Exchange Commission</a>. February 8, 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">August 26,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+Pharmaceuticals+2017+Annual+Report+Form+%2810-K%29&amp;rft.pub=U.S.+Securities+and+Exchange+Commission&amp;rft.date=2018-02-08&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F899866%2F000089986618000022%2Falxn10k12312017.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r935243608">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://fortune.com/fortune500/alexion-pharmaceuticals/">"Alexion Pharmaceuticals"</a>. <i>Fortune</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2019-02-09</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Fortune&amp;rft.atitle=Alexion+Pharmaceuticals&amp;rft_id=http%3A%2F%2Ffortune.com%2Ffortune500%2Falexion-pharmaceuticals%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.medicalnewstoday.com/articles/221849.php">"Alexion Submits Application for Soliris"</a>. 2011-04-08.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+Submits+Application+for+Soliris&amp;rft.date=2011-04-08&amp;rft_id=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F221849.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Forbes-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-Forbes_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Forbes_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.forbes.com/companies/alexion-pharmaceuticals/">"Alexion Pharmaceuticals on the Forbes World's Most Innovative Companies List"</a>. <i>forbes.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 September</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=forbes.com&amp;rft.atitle=Alexion+Pharmaceuticals+on+the+Forbes+World%E2%80%99s+Most+Innovative+Companies+List&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fcompanies%2Falexion-pharmaceuticals%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Everything-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-Everything_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Everything_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Everything_5-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Don Seiffert (May 6, 2015). <a rel="nofollow" class="external text" href="http://www.bizjournals.com/boston/blog/bioflash/2015/05/everything-you-need-to-know-about-the-8-4b.html">"Everything you need to know about the $8.4B acquisition of Synageva"</a>. <i>Boston Business Journal</i><span class="reference-accessdate">. Retrieved <span class="nowrap">May 8,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Boston+Business+Journal&amp;rft.atitle=Everything+you+need+to+know+about+the+%248.4B+acquisition+of+Synageva&amp;rft.date=2015-05-06&amp;rft.au=Don+Seiffert&amp;rft_id=http%3A%2F%2Fwww.bizjournals.com%2Fboston%2Fblog%2Fbioflash%2F2015%2F05%2Feverything-you-need-to-know-about-the-8-4b.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://photos.newhavenregister.com/2016/02/29/photos-of-alexion-pharmaceuticals-global-hq-dedication/#1">"Photos of Alexion Pharmaceuticals World HQ Dedication"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Photos+of+Alexion+Pharmaceuticals+World+HQ+Dedication&amp;rft_id=http%3A%2F%2Fphotos.newhavenregister.com%2F2016%2F02%2F29%2Fphotos-of-alexion-pharmaceuticals-global-hq-dedication%2F%231&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation news">Singer, Stephen (2017-09-12). <a rel="nofollow" class="external text" href="http://www.courant.com/news/connecticut/hc-alexion-moving-new-haven-boston-20170911-story.html">"Alexion Exits New Haven For Boston, Agrees To Repay Millions In State Aid"</a>. <i><a href="/wiki/Hartford_Courant" title="Hartford Courant">Hartford Courant</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-09-12</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hartford+Courant&amp;rft.atitle=Alexion+Exits+New+Haven+For+Boston%2C+Agrees+To+Repay+Millions+In+State+Aid&amp;rft.date=2017-09-12&amp;rft.aulast=Singer&amp;rft.aufirst=Stephen&amp;rft_id=http%3A%2F%2Fwww.courant.com%2Fnews%2Fconnecticut%2Fhc-alexion-moving-new-haven-boston-20170911-story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-medpage-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-medpage_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-medpage_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-medpage_8-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.medpagetoday.com/Cardiology/PCI/4638">"More Support for Long-Term Plavix to Improve Stent Safety"</a>. Dec 5, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">Jul 18,</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=More+Support+for+Long-Term+Plavix+to+Improve+Stent+Safety&amp;rft.date=2006-12-05&amp;rft_id=http%3A%2F%2Fwww.medpagetoday.com%2FCardiology%2FPCI%2F4638&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-:0-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_9-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Herper, Matthew. <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2012/09/05/how-a-440000-drug-is-turning-alexion-into-biotechs-new-innovation-powerhouse/#d3819ca25e11">"How A $440,000 Drug Is Turning Alexion Into Biotech's New Innovation Powerhouse"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-11-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=How+A+%24440%2C000+Drug+Is+Turning+Alexion+Into+Biotech%27s+New+Innovation+Powerhouse&amp;rft.aulast=Herper&amp;rft.aufirst=Matthew&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2012%2F09%2F05%2Fhow-a-440000-drug-is-turning-alexion-into-biotechs-new-innovation-powerhouse%2F%23d3819ca25e11&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-WSJ-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-WSJ_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WSJ_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-WSJ_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-WSJ_10-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-WSJ_10-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-WSJ_10-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-WSJ_10-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Chelsey Dulaney (May 6, 2015). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/alexion-to-buy-synageva-in-8-4-billion-biotech-deal-1430911447">"Alexion to Buy Synageva for $8.4 Billion"</a>. <i>The Wall Street Journal</i><span class="reference-accessdate">. Retrieved <span class="nowrap">May 7,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Wall+Street+Journal&amp;rft.atitle=Alexion+to+Buy+Synageva+for+%248.4+Billion&amp;rft.date=2015-05-06&amp;rft.au=Chelsey+Dulaney&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Falexion-to-buy-synageva-in-8-4-billion-biotech-deal-1430911447&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.hartfordbusiness.com/news18747.html">"Alexion treating Europe's E coli victims"</a>. 2011-05-31.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+treating+Europe%27s+E+coli+victims&amp;rft.date=2011-05-31&amp;rft_id=http%3A%2F%2Fwww.hartfordbusiness.com%2Fnews18747.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20110404061251/http://ir.nasdaqomx.com/releasedetail.cfm?ReleaseID=560664">"Alexion Pharmaceuticals, Inc. to Join the NASDAQ-100 Index Beginning April 4, 2011"</a>. 2011-03-29. Archived from <a rel="nofollow" class="external text" href="http://ir.nasdaqomx.com/releasedetail.cfm?ReleaseID=560664">the original</a> on April 4, 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">April 9,</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+Pharmaceuticals%2C+Inc.+to+Join+the+NASDAQ-100+Index+Beginning+April+4%2C+2011&amp;rft.date=2011-03-29&amp;rft_id=http%3A%2F%2Fir.nasdaqomx.com%2Freleasedetail.cfm%3FReleaseID%3D560664&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals">"Teva wins controversial PhRMA bid despite protests from branded rivals - FiercePharma"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Teva+wins+controversial+PhRMA+bid+despite+protests+from+branded+rivals+-+FiercePharma&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fteva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://news.alexionpharma.com/press-release/company-news/alexions-board-directors-announces-new-leadership-appointments">"Alexion's Board of Directors Announces New Leadership Appointments | Alexion Pharmaceuticals, Inc"</a>. <i>news.alexionpharma.com</i> (Press release)<span class="reference-accessdate">. Retrieved <span class="nowrap">2016-12-12</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion%E2%80%99s+Board+of+Directors+Announces+New+Leadership+Appointments+%7C+Alexion+Pharmaceuticals%2C+Inc&amp;rft_id=http%3A%2F%2Fnews.alexionpharma.com%2Fpress-release%2Fcompany-news%2Falexions-board-directors-announces-new-leadership-appointments&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation news">Grover, Natalie (March 27, 2017). <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-alexion-pharms-moves-ceo-idUSKBN16Y157">"Alexion Pharma names former Baxalta chief Ludwig Hantson CEO"</a>. Reuters<span class="reference-accessdate">. Retrieved <span class="nowrap">March 27,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Alexion+Pharma+names+former+Baxalta+chief+Ludwig+Hantson+CEO&amp;rft.date=2017-03-27&amp;rft.aulast=Grover&amp;rft.aufirst=Natalie&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-alexion-pharms-moves-ceo-idUSKBN16Y157&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20110818161444/http://ir.alexionpharm.com/secfiling.cfm?filingID=1005477-00-8099">"Alexion Buys Calif. Firm;Proliferon acquired in $41 million deal"</a>. 2000-02-10. Archived from <a rel="nofollow" class="external text" href="http://ir.alexionpharm.com/secfiling.cfm?filingID=1005477-00-8099">the original</a> on 2011-08-18<span class="reference-accessdate">. Retrieved <span class="nowrap">2011-04-09</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+Buys+Calif.+Firm%3BProliferon+acquired+in+%2441+million+deal&amp;rft.date=2000-02-10&amp;rft_id=http%3A%2F%2Fir.alexionpharm.com%2Fsecfiling.cfm%3FfilingID%3D1005477-00-8099&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20110818161444/http://ir.alexionpharm.com/secfiling.cfm?filingID=1005477-00-8099">"Securities and Exchange Commission Alexion 8-K 2000 Report"</a>. 2000-09-18. Archived from <a rel="nofollow" class="external text" href="http://ir.alexionpharm.com/secfiling.cfm?filingID=1005477-00-8099">the original</a> on 2011-08-18<span class="reference-accessdate">. Retrieved <span class="nowrap">2011-04-09</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Securities+and+Exchange+Commission+Alexion+8-K+2000+Report&amp;rft.date=2000-09-18&amp;rft_id=http%3A%2F%2Fir.alexionpharm.com%2Fsecfiling.cfm%3FfilingID%3D1005477-00-8099&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.businessweek.com/news/2011-12-29/alexion-to-pay-as-much-as-1-08-billion-to-buy-enobia-pharma.html">"Alexion to Pay as Much as $1.08 Billion to Buy Enobia Pharma"</a>. <i>Business Week</i>. December 29, 2011.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Business+Week&amp;rft.atitle=Alexion+to+Pay+as+Much+as+%241.08+Billion+to+Buy+Enobia+Pharma&amp;rft.date=2011-12-29&amp;rft_id=http%3A%2F%2Fwww.businessweek.com%2Fnews%2F2011-12-29%2Falexion-to-pay-as-much-as-1-08-billion-to-buy-enobia-pharma.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-bostonglobe_2015-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-bostonglobe_2015_19-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Robert Weisman (12 July 2015). <a rel="nofollow" class="external text" href="https://www.bostonglobe.com/business/2015/07/11/genzyme-family-tree-how-henri-termeer-spawned-network-genzyme-alums-leading-dozens-biotechs-from-cambridge-stockholm/Dkoz2zcLlNz3N6OZbOvN4L/story.html#">"How Genzyme became a source of biotech executives"</a>. <i>The Boston Globe</i><span class="reference-accessdate">. Retrieved <span class="nowrap">17 July</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Boston+Globe&amp;rft.atitle=How+Genzyme+became+a+source+of+biotech+executives&amp;rft.date=2015-07-12&amp;rft.au=Robert+Weisman&amp;rft_id=https%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2015%2F07%2F11%2Fgenzyme-family-tree-how-henri-termeer-spawned-network-genzyme-alums-leading-dozens-biotechs-from-cambridge-stockholm%2FDkoz2zcLlNz3N6OZbOvN4L%2Fstory.html%23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYT-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYT_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT_20-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NYT_20-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NYT_20-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NYT_20-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Robert Cyran (May 6, 2015). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html">"Alexion Puts Its Soaring Stock Price to Good Use"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">May 7,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Alexion+Puts+Its+Soaring+Stock+Price+to+Good+Use&amp;rft.date=2015-05-06&amp;rft.au=Robert+Cyran&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F05%2F07%2Fbusiness%2Fdealbook%2Falexion-puts-its-soaring-stock-price-to-good-use.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation news">Hirschler, Ben. <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-wilson-therapeut-m-a-alexion-pharms/biotech-ma-rolls-on-as-alexion-snaps-up-wilson-for-855-million-idUSKBN1HI236">"Biotech M&amp;A rolls on as Alexion snaps up Wilson for $855 million"</a>. <i>U.S</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-04-11</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=U.S.&amp;rft.atitle=Biotech+M%26A+rolls+on+as+Alexion+snaps+up+Wilson+for+%24855+million&amp;rft.aulast=Hirschler&amp;rft.aufirst=Ben&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-wilson-therapeut-m-a-alexion-pharms%2Fbiotech-ma-rolls-on-as-alexion-snaps-up-wilson-for-855-million-idUSKBN1HI236&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.genengnews.com/gen-news-highlights/alexion-to-acquire-wilson-therapeutics-for-855m/81255689">"Alexion to Acquire Wilson Therapeutics for $855M - GEN"</a>. <i>GEN</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=GEN&amp;rft.atitle=Alexion+to+Acquire+Wilson+Therapeutics+for+%24855M+-+GEN&amp;rft_id=https%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Falexion-to-acquire-wilson-therapeutics-for-855m%2F81255689&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.genengnews.com/news/alexion-to-acquire-syntimmune-for-up-to-1-2b-expanding-rare-disease-pipeline/">"Alexion to Acquire Syntimmune for Up to $1.2B, Expanding Rare Disease Pipeline"</a>. 26 September 2018.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+to+Acquire+Syntimmune+for+Up+to+%241.2B%2C+Expanding+Rare+Disease+Pipeline&amp;rft.date=2018-09-26&amp;rft_id=https%3A%2F%2Fwww.genengnews.com%2Fnews%2Falexion-to-acquire-syntimmune-for-up-to-1-2b-expanding-rare-disease-pipeline%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://uk.reuters.com/article/us-syntimmune-m-a-alexion-pharms-idUKKCN1M61DU">"Alexion to buy biotech firm Syntimmune for up to $1.2 billion"</a>. 26 September 2018 – via uk.reuters.com.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+to+buy+biotech+firm+Syntimmune+for+up+to+%241.2+billion&amp;rft.date=2018-09-26&amp;rft_id=https%3A%2F%2Fuk.reuters.com%2Farticle%2Fus-syntimmune-m-a-alexion-pharms-idUKKCN1M61DU&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://www.biospace.com/article/alexion-buys-achillion-in-930-million-cash-deal/?s=79">https://www.biospace.com/article/alexion-buys-achillion-in-930-million-cash-deal/?s=79</a></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.nasdaq.com/symbol/alxn/ownership-summary">"Alexion Pharmaceuticals, Inc. (ALXN) Ownership Summary"</a>. <i>NASDAQ.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NASDAQ.com&amp;rft.atitle=Alexion+Pharmaceuticals%2C+Inc.+%28ALXN%29+Ownership+Summary&amp;rft_id=http%3A%2F%2Fwww.nasdaq.com%2Fsymbol%2Falxn%2Fownership-summary&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Forbes_2010-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-Forbes_2010_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Forbes_2010_27-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Forbes_2010_27-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFHerper2010" class="citation">Herper, Matthew (February 19, 2010), <a rel="nofollow" class="external text" href="https://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html">"The World's Most Expensive Drugs"</a>, <i>Forbes</i><span class="reference-accessdate">, retrieved <span class="nowrap">June 25,</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=The+World%27s+Most+Expensive+Drugs&amp;rft.date=2010-02-19&amp;rft.aulast=Herper&amp;rft.aufirst=Matthew&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2F2010%2F02%2F19%2Fexpensive-drugs-cost-business-healthcare-rare-diseases.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.zacks.com/stock/news/50969/Alexion+Seeks+Label+Expansion">"Alexion Seeks Label Expansion"</a>. 2011-04-08.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Alexion+Seeks+Label+Expansion&amp;rft.date=2011-04-08&amp;rft_id=http%3A%2F%2Fwww.zacks.com%2Fstock%2Fnews%2F50969%2FAlexion%2BSeeks%2BLabel%2BExpansion&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-CBC_2015-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-CBC_2015_29-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFKelly_Crowe2015" class="citation">Kelly Crowe (25 June 2015), <a rel="nofollow" class="external text" href="http://www.cbc.ca/news/health/how-pharmaceutical-company-alexion-set-the-price-of-the-world-s-most-expensive-drug-1.3125251"><i>A Price to Pay: how the manufacturer pulls on emotions - patients, families, politicians and governments around the world</i></a>, CBC News<span class="reference-accessdate">, retrieved <span class="nowrap">18 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=A+Price+to+Pay%3A+how+the+manufacturer+pulls+on+emotions+-+patients%2C+families%2C+politicians+and+governments+around+the+world&amp;rft.pub=CBC+News&amp;rft.date=2015-06-25&amp;rft.au=Kelly+Crowe&amp;rft_id=http%3A%2F%2Fwww.cbc.ca%2Fnews%2Fhealth%2Fhow-pharmaceutical-company-alexion-set-the-price-of-the-world-s-most-expensive-drug-1.3125251&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.businesswire.com/news/home/20110923005612/en/Soliris%C2%AE-eculizumab-Approved-FDA-Patients-Atypical-Hemolytic">"Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)"</a>. September 23, 2011.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Soliris%C2%AE+%28eculizumab%29+Approved+by+FDA+for+All+Patients+with+Atypical+Hemolytic+Uremic+Syndrome+%28aHUS%29&amp;rft.date=2011-09-23&amp;rft_id=http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20110923005612%2Fen%2FSoliris%25C2%25AE-eculizumab-Approved-FDA-Patients-Atypical-Hemolytic&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-irishtimes.com-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-irishtimes.com_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-irishtimes.com_31-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.irishtimes.com/news/politics/doctors-must-tell-patients-of-errors-under-new-law-from-varadkar-1.2092525">"Doctors must tell patients of errors, under new Varadkar law"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Doctors+must+tell+patients+of+errors%2C+under+new+Varadkar+law&amp;rft_id=http%3A%2F%2Fwww.irishtimes.com%2Fnews%2Fpolitics%2Fdoctors-must-tell-patients-of-errors-under-new-law-from-varadkar-1.2092525&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-nice.org.uk-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-nice.org.uk_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-nice.org.uk_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.nice.org.uk/news/press-and-media/high-cost-of-treatment-for-rare-blood-disorder-needs-to-be-clarified-says-nice-in-draft-guidance">"High cost of treatment for rare blood disorder needs to be clarified, says NICE in draft guidance"</a>. <i>nice.org.uk</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=nice.org.uk&amp;rft.atitle=High+cost+of+treatment+for+rare+blood+disorder+needs+to+be+clarified%2C+says+NICE+in+draft+guidance&amp;rft_id=http%3A%2F%2Fwww.nice.org.uk%2Fnews%2Fpress-and-media%2Fhigh-cost-of-treatment-for-rare-blood-disorder-needs-to-be-clarified-says-nice-in-draft-guidance&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Gallant_2014-33"><span class="mw-cite-backlink">^ <a href="#cite_ref-Gallant_2014_33-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Gallant_2014_33-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFGallant2014" class="citation">Gallant, Jacques (December 4, 2014), <a rel="nofollow" class="external text" href="https://www.thestar.com/news/gta/2014/12/04/toronto_woman_with_rare_disease_fights_province_for_lifesaving_but_costly_drug.html"><i>Toronto woman with rare disease fights province for life-saving but costly drug Soliris, which costs $500,000 a year, would treat Toni Vernon's blood disease, but the health ministry is holding back</i></a><span class="reference-accessdate">, retrieved <span class="nowrap">June 25,</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Toronto+woman+with+rare+disease+fights+province+for+life-saving+but+costly+drug+Soliris%2C+which+costs+%24500%2C000+a+year%2C+would+treat+Toni+Vernon%27s+blood+disease%2C+but+the+health+ministry+is+holding+back&amp;rft.date=2014-12-04&amp;rft.aulast=Gallant&amp;rft.aufirst=Jacques&amp;rft_id=https%3A%2F%2Fwww.thestar.com%2Fnews%2Fgta%2F2014%2F12%2F04%2Ftoronto_woman_with_rare_disease_fights_province_for_lifesaving_but_costly_drug.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://deredactie.be/cm/vrtnieuws/binnenland/1.1617223">"Viktor (7) moet elke twee weken infuus krijgen van 9.000 euro"</a>. April 30, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Viktor+%287%29+moet+elke+twee+weken+infuus+krijgen+van+9.000+euro&amp;rft.date=2013-04-30&amp;rft_id=http%3A%2F%2Fderedactie.be%2Fcm%2Fvrtnieuws%2Fbinnenland%2F1.1617223&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.standaard.be/cnt/DMF20130504_00566977">"Pr-bureau van farmabedrijf adviseerde ook ouders Viktor"</a>. May 4, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pr-bureau+van+farmabedrijf+adviseerde+ook+ouders+Viktor&amp;rft.date=2013-05-04&amp;rft_id=http%3A%2F%2Fwww.standaard.be%2Fcnt%2FDMF20130504_00566977&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://deredactie.be/cm/vrtnieuws/binnenland/130504_Alexion_Viktor">"Farmabedrijf Alexion heeft Viktor "gebruikt<span class="cs1-kern-right">"</span>"</a>. May 4, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Farmabedrijf+Alexion+heeft+Viktor+%22gebruikt%22&amp;rft.date=2013-05-04&amp;rft_id=http%3A%2F%2Fderedactie.be%2Fcm%2Fvrtnieuws%2Fbinnenland%2F130504_Alexion_Viktor&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.standaard.be/cnt/DMF20130506_00568721">"Farmabaas fluit Alexion terug in zaak-Viktor"</a>. May 6, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Farmabaas+fluit+Alexion+terug+in+zaak-Viktor&amp;rft.date=2013-05-06&amp;rft_id=http%3A%2F%2Fwww.standaard.be%2Fcnt%2FDMF20130506_00568721&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://deredactie.be/cm/vrtnieuws/binnenland/1.1619457">"Detiège: "Dit is chantage van het farmabedrijf<span class="cs1-kern-right">"</span>"</a>. May 2, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Deti%C3%A8ge%3A+%22Dit+is+chantage+van+het+farmabedrijf%22&amp;rft.date=2013-05-02&amp;rft_id=http%3A%2F%2Fderedactie.be%2Fcm%2Fvrtnieuws%2Fbinnenland%2F1.1619457&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.standaard.be/cnt/DMF20130507_00570744">"Medicijn Viktor vanaf juli terugbetaald"</a>. May 7, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Medicijn+Viktor+vanaf+juli+terugbetaald&amp;rft.date=2013-05-07&amp;rft_id=http%3A%2F%2Fwww.standaard.be%2Fcnt%2FDMF20130507_00570744&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-dm20150323-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-dm20150323_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-dm20150323_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.demorgen.be/binnenland/-contract-van-onkelinx-met-farmareus-opent-doos-van-pandora-a2261432/">"Contract van Onkelinx met farmareus opent doos van Pandora"</a>. 2015-03-23<span class="reference-accessdate">. Retrieved <span class="nowrap">2015-03-24</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Contract+van+Onkelinx+met+farmareus+opent+doos+van+Pandora&amp;rft.date=2015-03-23&amp;rft_id=http%3A%2F%2Fwww.demorgen.be%2Fbinnenland%2F-contract-van-onkelinx-met-farmareus-opent-doos-van-pandora-a2261432%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.standaard.be/cnt/dmf20131001_00768977">"Spreekverbod Pharma.be opgeheven"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-03-24</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Spreekverbod+Pharma.be+opgeheven&amp;rft_id=http%3A%2F%2Fwww.standaard.be%2Fcnt%2Fdmf20131001_00768977&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation news">Bruno, Giovanni (2017-10-24). <a rel="nofollow" class="external text" href="https://www.thestreet.com/story/14356628/1/alexion-pharmaceuticals-stock-jumps-on-fda-approval-of.html">"Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris"</a>. <i>TheStreet</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-11-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=TheStreet&amp;rft.atitle=Alexion+Pharmaceuticals+Stock+Jumps+on+FDA+Approval+of+Soliris&amp;rft.date=2017-10-24&amp;rft.aulast=Bruno&amp;rft.aufirst=Giovanni&amp;rft_id=https%3A%2F%2Fwww.thestreet.com%2Fstory%2F14356628%2F1%2Falexion-pharmaceuticals-stock-jumps-on-fda-approval-of.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.streetinsider.com/Corporate+News/Alexion+Pharma+(ALXN)+Receives+New+Japanese+Patent+for+Soliris/13466411.html">"Alexion Pharma (ALXN) Receives New Japanese Patent for Soliris"</a>. <i>StreetInsider.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-11-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=StreetInsider.com&amp;rft.atitle=Alexion+Pharma+%28ALXN%29+Receives+New+Japanese+Patent+for+Soliris&amp;rft_id=https%3A%2F%2Fwww.streetinsider.com%2FCorporate%2BNews%2FAlexion%2BPharma%2B%28ALXN%29%2BReceives%2BNew%2BJapanese%2BPatent%2Bfor%2BSoliris%2F13466411.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-AP-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-AP_44-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Tom Murphy (May 7, 2015). <a rel="nofollow" class="external text" href="https://www.usatoday.com/story/money/business/2015/05/06/alexion-synageva/70909976/">"Biotech blastoff: Synageva up 112% on $8B Alexion deal"</a>. <i>USA Today</i>. AP<span class="reference-accessdate">. Retrieved <span class="nowrap">May 7,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=USA+Today&amp;rft.atitle=Biotech+blastoff%3A+Synageva+up+112%25+on+%248B+Alexion+deal&amp;rft.date=2015-05-07&amp;rft.au=Tom+Murphy&amp;rft_id=https%3A%2F%2Fwww.usatoday.com%2Fstory%2Fmoney%2Fbusiness%2F2015%2F05%2F06%2Falexion-synageva%2F70909976%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20150913202213/http://ir.alexionpharm.com/secfiling.cfm?filingid=899866-14-34">"Alexion Pharmaceuticals, Inc. - Annual Report"</a>. <i>ir.alexionpharm.com</i>. Archived from <a rel="nofollow" class="external text" href="http://ir.alexionpharm.com/secfiling.cfm?filingID=899866-14-34">the original</a> on 2015-09-13<span class="reference-accessdate">. Retrieved <span class="nowrap">2016-11-04</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=ir.alexionpharm.com&amp;rft.atitle=Alexion+Pharmaceuticals%2C+Inc.+-+Annual+Report&amp;rft_id=http%3A%2F%2Fir.alexionpharm.com%2Fsecfiling.cfm%3FfilingID%3D899866-14-34&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAlexion+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
</ol></div></div>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(6)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><a href="/w/index.php?title=Alexion_Pharmaceuticals&amp;action=edit&amp;section=12" title="Edit section: External links" data-section="12" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-6 collapsible-block" id="mf-section-6">
<ul><li><a rel="nofollow" class="external text" href="http://www.alxn.com">Official website</a></li>
<li>Business data for Alexion Pharmaceuticals: <div class="hlist hlist-separated inline"><ul><li><a rel="nofollow" class="external text" href="https://www.google.com/finance?q=ALXN">Google Finance</a></li><li><a rel="nofollow" class="external text" href="https://finance.yahoo.com/q?s=ALXN">Yahoo! Finance</a></li><li><a rel="nofollow" class="external text" href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=ALXN">SEC filings</a></li></ul></div></li>
<li><a rel="nofollow" class="external text" href="https://stockrow.com/ALXN">ALXN on Stockrow</a> &amp; <a rel="nofollow" class="external text" href="http://www.wikinvest.com/stock/Alexion_Pharmaceuticals_(ALXN)">Wikinvest</a></li></ul>





</section></div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1&amp;mobile=1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&amp;oldid=946921704">https://en.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&amp;oldid=946921704</a>"</div>
</div>
			<div class="post-content" id="page-secondary-actions">
			
			</div>
		</main>
		<footer class="minerva-footer">
		<div class="last-modified-bar">
	<div class="post-content last-modified-bar__content">
		<span class="last-modified-bar__icon mw-ui-icon mw-ui-icon-mw-ui-icon-small mw-ui-icon-wikimedia-history-base20 "></span>
		<a class="last-modified-bar__text" href="/wiki/Special:History/Alexion_Pharmaceuticals"
				data-user-name="2601:188:180:B8E0:75BB:4BD0:D3CD:79D"
				data-user-gender="unknown"
				data-timestamp="1584939744">
				<span>Last edited on 23 March 2020, at 05:02</span>
		</a>
		<span class="mw-ui-icon mw-ui-icon-small mw-ui-icon-mf-expand-gray mf-mw-ui-icon-rotate-anti-clockwise indicator"></span>
	</div>
</div>

		<div class="post-content footer-content">
			<div id='mw-data-after-content'>
	<div class="read-more-container"></div>
</div>

			<h2><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></h2>
			<div class="license">Content is available under <a class="external" rel="nofollow" href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a> unless otherwise noted.</div>
			<ul class="footer-places hlist hlist-separated">
				<li id="footer-places-terms-use"><a href="//m.wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a></li><li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy</a></li><li id="footer-places-desktop-toggle"><a id="mw-mf-display-toggle" href="//en.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&amp;mobileaction=toggle_view_desktop">Desktop</a></li>
			</ul>
		</div>
		</footer>
	</div>
</div>
<div class="mw-notification-area" data-mw="interface"></div>
<!-- v:8.3.0 -->

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.724","walltime":"0.894","ppvisitednodes":{"value":3148,"limit":1000000},"postexpandincludesize":{"value":168152,"limit":2097152},"templateargumentsize":{"value":4843,"limit":2097152},"expansiondepth":{"value":22,"limit":40},"expensivefunctioncount":{"value":1,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":168157,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00%  759.086      1 -total"," 56.04%  425.390     16 Template:Clade"," 44.18%  335.359      1 Template:Reflist"," 24.82%  188.385     28 Template:Cite_web"," 22.86%  173.549      1 Template:Infobox_company"," 20.82%  158.054      1 Template:Infobox","  9.17%   69.637      7 Template:Wikidata","  8.80%   66.823      1 Template:Br_separated_entries","  8.37%   63.527     12 Template:Cite_news","  6.98%   52.970      1 Template:Short_description"]},"scribunto":{"limitreport-timeusage":{"value":"0.383","limit":"10.000"},"limitreport-memusage":{"value":7837866,"limit":52428800}},"cachereport":{"origin":"mw1261","timestamp":"20200416051349","ttl":2592000,"transientcontent":false}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Alexion Pharmaceuticals","url":"https:\/\/en.wikipedia.org\/wiki\/Alexion_Pharmaceuticals","sameAs":"http:\/\/www.wikidata.org\/entity\/Q204727","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q204727","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2011-04-09T06:19:28Z","dateModified":"2020-03-23T05:02:24Z","headline":"American company"}</script><script>(window.NORLQ=window.NORLQ||[]).push(function(){var ns,i,p,img;ns=document.getElementsByTagName('noscript');for(i=0;i<ns.length;i++){p=ns[i].nextSibling;if(p&&p.className&&p.className.indexOf('lazy-image-placeholder')>-1){img=document.createElement('img');img.setAttribute('src',p.getAttribute('data-src'));img.setAttribute('width',p.getAttribute('data-width'));img.setAttribute('height',p.getAttribute('data-height'));img.setAttribute('alt',p.getAttribute('data-alt'));p.parentNode.replaceChild(img,p);}}});</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":122,"wgHostname":"mw1322"});});</script>		</body>
		</html>
		